Answers are grounded in this paper and cite their sources.
The effectiveness and adverse effects of VIT in patients with Hymenoptera venom allergy and cancer in remission are comparable to those of patients without malignancy. Our findings show that patients with Hymenoptera venom allergy and cancer are eligible for VIT.
No takes yet. Share an insight, caveat, or question.
Aeberhard et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: